Identifying determinants of long-term viral suppression following broadly neutralizing antibody treatment against HIV-1

Due to their long circulating half-life, high neutralization potency, and large breadth of coverage, broadly neutralizing antibodies are increasingly studied for the treatment of HIV-1 infection. Recent phase I clinical studies of antibody treatment have demonstrated robust and durable antiviral effects in viremic participants and in participants undergoing analytical treatment interruption. Consequently, these antibodies are an attractive novel treatment candidate for long-term, antiretroviral therapy-free, viral control. However, these early-stage trials are small, time consuming, and expensive. I'll show how mechanistic mathematical modelling can identify clinically actionable determinants of treatment response and uncover the evolutionary dynamics driving viral rebound.

MBIM Seminar series